Abstract
Safinamide is a new drug approved for the treatment of Parkinson's disease (PD) with fluctuations as an adjunct to levodopa alone or in combination with other drugs.1 When fluctuations arise, several therapeutic options can be taken. Safinamide is a MAO-B inhibitor and glutamate modulator which may allow lower doses of levodopa and dopaminergic agonists to be used, minimizing side effects that emerge frequently with high doses of these drugs.2.3
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
